Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab and Vorolanib Neoadjuvant Therapy for High-risk Renal Carcinoma
NCT07386158Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab and vorolanib in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
pucotenlimabvorolanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07386158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07386158.